Supply Chain Research

A new Executive Order from President Trump will seek to control drug pricing. That may pull the generic drugmakers that export to the U.S. in two directions. A desire for cheaper drugs will help them, while new rules on intellectual property may make the formulation of new generic drugs more difficult. The top 12 generic pharma companies tracked by Panjiva saw a 6% rise in shipments to the U.S. in the three months through May, led by a 64% jump from Aurobindo. Yet, they are increasingly reliant on products outside the traditional big four (statins, P-PIs, anticonvulsants and insulins), i...